Please Wait.....
Report
Global Anti-hypertensive Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
Market Report I 2025-06-01 I 130 Pages I Mordor Intelligence
Global Anti-hypertensive Drugs Market Analysis
The antihypertensive drugs market is valued at USD 26.69 billion in 2025 and is forecast to reach USD 31.69 billion in 2030, advancing at a 3.5% CAGR. Uptake is anchored in escalating hypertension prevalence, an older global population, and steady innovation in fixed-dose combinations that improve adherence. Emerging long-acting injectable therapies and AI-enabled dose-titration platforms add fresh clinical value while generic competition tempers overall price growth. Asia-Pacific outpaces other regions on the back of rapid urbanization, salt-heavy diets, and widening health-insurance schemes. Meanwhile, North America sustains the largest revenue pool through early adoption of novel mechanisms, broad reimbursement, and entrenched cardiology care pathways. Throughout 2025-2030, companies with balanced portfolios of breakthrough assets and cost-competitive generics are positioned to capture incremental demand, even as patent cliffs squeeze margins for older brands.
Global Anti-hypertensive Drugs Market Trends and Insights
Accelerating Obesity and Metabolic Syndrome
Metabolic syndrome affects roughly one-third of adults worldwide, and hypertension co-exists in 85% of these patients. Clinicians are moving toward agents that simultaneously address weight, glycemic control, and blood pressure, particularly GLP-1 receptor agonists that cut systolic readings by 7-10 mmHg independent of weight loss. Health-system models estimate that unchecked hypertension could push annual cardiovascular treatment costs from USD 160 billion in 2020 to USD 513 billion by 2050, reinforcing the economic case for aggressive early therapy .
Growth of Fixed-Dose Combination Therapies
Roughly 70% of patients need two or more antihypertensive agents, yet adherence drops as pill count rises. FDA approval of the first triple-combination tablet in 2025 signals a regulatory green light for upfront multi-drug products that achieved 70% control rates versus 37% on placebo. Health-economic studies put annual hospitalization savings at USD 873 per adherent patient, spurring payers to prioritize such regimens.
Patent Cliffs for Blockbuster ARBs & CCBs
Entresto loses U.S. exclusivity in mid-2025, and multiple ARB and CCB molecules face similar expiries, inviting rapid generic entry that historically erodes branded volume by up to 90% within a year. Manufacturers are countering with novel formulations and combination products, though payers favor generics for cost control.
Other drivers and restraints analyzed in the detailed report include:
Expanding Reimbursement for Single-Pill Regimens / Uptake of Once-Weekly GLP-1 Combination Injectables / Low Adherence Due to Asymptomatic Nature of Hypertension /
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
Angiotensin II Receptor Blockers held 31.43% antihypertensive drugs market share in 2024 thanks to proven cardio-renal benefits and favorable tolerability. Renin Inhibitors, although smaller, will climb at 4.23% CAGR as physicians adopt new pathways for resistant patients. Endothelin receptor antagonists and aldosterone synthase inhibitors, newly approved in 2025, bring additional options for hard-to-treat cases. Beta Blockers and some older Calcium Channel Blockers lose ground due to metabolic side effects, while diuretics gain renewed interest through low-dose formulations. Pipeline diversity underscores a shift toward precision mechanisms addressing comorbidity clusters and resistant hypertension niches.
The antihypertensive drugs market continues to reward classes that combine efficacy with favorable side-effect profiles. Lifecycle strategies now favor triple-combination tablets that integrate ARBs with CCBs or diuretics, anchoring brand loyalty even amid generic pressure. Novel mechanisms are expected to command premium pricing where they demonstrate clear outcome advantages, cushioning revenue against pending patent expiries. Manufacturers with broad portfolios straddling generics and innovations will navigate the transition most effectively.
The Antihypertensive Drugs Market Report Segments the Industry Into Therapeutic Class (Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs) and More), by Distribution Channel (Hospital Pharmacies and More), by Route of Administration (Oral, Parenteral / Injectable and More) and Geography (North America, Europe, Asia-Pacific and More). The Market Forecasts are Provided in Terms of Value (USD).
Geography Analysis
North America captured 35.55% of 2024 revenue, leveraging sophisticated cardiology networks, strong insurance coverage, and fast uptake of novel classes. The United States leads, buoyed by premium prices and early use of digital health. Canada emphasizes cost-effectiveness, leaning on generics, while Mexico grows volume as coverage expands across public programs.
Europe contributes steady mid-single-digit growth under mature health systems that weigh cost and innovation in equal measure. Germany and the United Kingdom spearhead clinical adoption of advanced mechanisms, whereas Southern Europe leans on high generic penetration. Value-based contracting accelerates fixed-dose uptake in major EU markets.
Asia-Pacific stands out as the fastest-expanding region with a 5.67% CAGR. China's bulk-procurement policies have cut prices yet boosted volumes, while India benefits from large-scale manufacturing and rising domestic demand. Japan's aging demographic sustains spending on cardio-metabolic care. Local salt-sensitivity profiles and genetic variations prompt region-specific research programs, creating scope for differentiated therapies.
South America shows gradual improvement amid economic recovery and hypertension awareness campaigns, though currency volatility tempers premium-drug uptake. Middle East and Africa remain nascent but promising as governments invest in non-communicable disease control and private insurance penetration rises.
List of Companies Covered in this Report:
Cepheid (Danaher) / Roche / Beckton Dickinson / Abbott Laboratories / Hologic / QIAGEN / Thermo Fisher Scientific / bioMerieux / Siemens Healthineers / Beckman Coulter Diagnostics / FUJIFILM / SD Biosensor / Molbio Diagnostics / Oxford Immunotec / Meridian Bioscience / LumiraDx / Tauns Laboratories / QuantuMDx / Luminex (DiaSorin) /
Additional Benefits:
The market estimate (ME) sheet in Excel format /
3 months of analyst support /
1 Introduction
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising prevalence of drug-resistant TB strains
4.2.2 WHO endorsement & national roll-outs of NAAT platforms
4.2.3 Government funding & global health initiatives
4.2.4 Emergence of AI-powered microscopy & digital radiology triage
4.2.5 Decentralised near-POC molecular platforms
4.2.6 Subscription-based diagnostics-as-a-service models
4.3 Market Restraints
4.3.1 High cost of molecular tests & cartridges
4.3.2 Shortage of skilled laboratory infrastructure
4.3.3 Supply-chain fragility for single-source cartridges
4.3.4 Competition from emerging non-sputum biomarkers
4.4 Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Suppliers
4.7.3 Bargaining Power of Buyers
4.7.4 Threat of Substitutes
4.7.5 Competitive Rivalry
5 Market Size & Growth Forecasts
5.1 By Test Type (Value)
5.1.1 Culture-based Tests
5.1.2 Smear Microscopy
5.1.3 Nucleic Acid Amplification Tests (NAAT)/PCR
5.1.4 Interferon-Gamma Release Assays (IGRA)
5.1.5 Tuberculin Skin Test (Mantoux)
5.1.6 Radiographic & Imaging Tests
5.1.7 Other Tests
5.2 By Technology (Value)
5.2.1 Culture-based
5.2.2 Molecular Diagnostics (PCR/NAAT)
5.2.3 Immunoassays (IGRA/LAM)
5.2.4 Radiology/X-ray
5.2.5 AI-enhanced Digital Microscopy
5.2.6 Others
5.3 By End-User (Value)
5.3.1 Hospitals & Clinics
5.3.2 Diagnostic Laboratories
5.3.3 Academic & Research Institutes
5.3.4 Others
5.4 By Geography (Value)
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 India
5.4.3.3 Japan
5.4.3.4 South Korea
5.4.3.5 Australia
5.4.3.6 Rest of Asia-Pacific
5.4.4 South America
5.4.4.1 Brazil
5.4.4.2 Argentina
5.4.4.3 Rest of South America
5.4.5 Middle East and Africa
5.4.5.1 GCC
5.4.5.2 South Africa
5.4.5.3 Rest of Middle East and Africa
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)}
6.3.1 Cepheid (Danaher)
6.3.2 Roche Diagnostics
6.3.3 Becton, Dickinson and Company
6.3.4 Abbott Laboratories
6.3.5 Hologic Inc.
6.3.6 Qiagen N.V.
6.3.7 Thermo Fisher Scientific Inc.
6.3.8 BioMerieux SA
6.3.9 Siemens Healthineers
6.3.10 Beckman Coulter Diagnostics
6.3.11 Fujifilm Holdings Corporation
6.3.12 SD Biosensor
6.3.13 Molbio Diagnostics
6.3.14 Oxford Immunotec
6.3.15 Meridian Bioscience
6.3.16 LumiraDx
6.3.17 Tauns Laboratories
6.3.18 QuantuMDx
6.3.19 Luminex (DiaSorin)
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-Need Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security